Tag Archives: Medical Research

Gonzales, Holmes & Muhoza Win 2025 Top Postdoctoral Awards

The NPA names in Boston the winners of its NPA Gallagher Mentor Award, NPA Distinguished Service Award, and NPA SCRI Postdoc of the Year Award

BOSTON, Mass., March 21, 2025 (SEND2PRESS NEWSWIRE) — During its annual conference, the National Postdoctoral Association (NPA) announced that Albert L. Gonzales, Ph.D., Christine Holmes, MBA, and Sixbert P. Muhoza, Ph.D., are the 2025 winners of the organization’s three most prestigious awards.

Image caption: National Postdoctoral Association (NPA).

“The NPA is committed to improving the postdoctoral experience and these three awards acknowledge the critical role postdocs and those who support them play in advancing knowledge and improving the human condition,” said Christopher T. Smith, Ph.D., chair of the NPA board. “Congratulations to this year’s well-deserved winners.”

The NPA Gallagher Mentor Award recognizes the very best of mentors across the nation who advocate for postdoctoral scholars, celebrate diversity, equity, inclusion, and belonging (DEIB) values, and empower their postdoc scholars to succeed. The NPA is dedicated to both recognizing champions and serving as a model for greater DEIB across the postdoctoral community.

This year’s award was presented to Albert. L. Gonzales, assistant professor, department of physiology and cellular biology, at the University of Nevada, Reno. In the words of those supporting Gonzales for the Gallagher Mentor Award, “his philosophy is rooted in the belief that diversity of thought enhances scientific inquiry and innovation.” Another noted: “His mentorship has enriched the postdoctoral experience at our institution by setting a standard of excellence that inspires all who work with him.”

The NPA Distinguished Service Award recognizes the highest appreciation for an individual who has demonstrated a profound, sustained, or leadership contribution to improving the postdoctoral experience. Today, that honor was bestowed on Christine Holmes, MBA, director for postdoctoral studies at Cornell University.

Holmes received the award today to a field of applauding peers who celebrated her decades of support for the postdoctoral community. Holmes founded the Office of Postdoctoral Studies at Cornell when she became its first director in 1995. “She created important new structures to uplift and support postdoctoral scholars on a shoestring budget,” according to her peers who nominated her. “She has had a uniquely profound and sustained impact … on the lives of thousands of early-career scholars.”

This year, the NPA and Seattle Children’s Research Institute (SCRI) presented its second annual Postdoc of the Year Award, bestowing that honor on Sixbert P. Muhoza, Ph.D., a Walter Massey Fellow at the Argonne National Laboratory. The NPA SCRI award recognizes a postdoc who has advanced the postdoctoral community in an exceptional manner beyond their work duties and in alignment with the NPA mission and core values.

In nominating Muhoza for this prestigious award, faculty members applauded his innovation and dedication, noting that he “has made substantial contributions to the scientific community and beyond during his fellowship, setting a new standard for postdoctoral excellence.”

“It’s an honor simply to work alongside these three individuals in the postdoctoral community,” said Tom Kimbis, executive director and chief executive officer of the NPA. “Holmes, Gonzales, and Muhoza are among the best of the best. Their excellence demonstrates the irreplaceable role of postdocs in the greater research environment. Postdocs are essential for maintaining American leadership in the sciences and beyond.”

Individuals and organizations can follow the work of Holmes, Gonzales, and Muhoza online by collaborating with the NPA, which is committed to advancing the skills and careers of our nation’s hard-working postdoctoral scholars, whose work in all disciplines benefits Americans across all fifty states.

About the National Postdoctoral Association:

The National Postdoctoral Association (NPA) is a nonprofit, 501(c)(3) charitable and educational association headquartered in Bethesda, MD. Founded in 2003, the NPA envisions an inclusive community where all postdocs are empowered, valued, recognized, and supported in their current and future endeavors. The NPA serves the entire postdoctoral community, including its 24,000 individual and 250 organizational members.

Learn more: https://www.nationalpostdoc.org/

LOGO link for media: https://www.send2press.com/300dpi/20-0916s2p-natpostdoc-logo-300dpi.jpg

NEWS SOURCE: National Postdoctoral Association

This press release was issued on behalf of the news source (National Postdoctoral Association), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/gonzales-holmes-muhoza-win-2025-top-postdoctoral-awards/

Biogen VP to Keynote 2025 Bioelectronic Medicine Forum in NYC

NEW YORK, N.Y., March 17, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Eighth Annual Bioelectronic Medicine Forum will take place on April 10, 2025. The one-day event will be held at the New York Academy of Medicine in Manhattan.

Image caption: Medtech and pharmaceutical industry executive Lisa Shafer, Ph.D., will keynote the 2025 Bioelectronic Medicine Forum in New York City on April 10.

Lisa Shafer, a vice president at biotech firm Biogen, will keynote the conference. Shafer has held executive management positions at key pharmaceutical firms such as Teva as well as neurotech firms such as Medtronic. In her distinguished career, she has helped bridge the gap between device and drug therapies as a chief scientific officer and product development executive. She earned her Ph.D. in neuroscience and neuroimmunology from Loyola University.

German firm Precisis, OSA startup LunOSA, European neuroprosthetics firm ReVision, and focused ultrasound firm Sanmai will present for the first time at the meeting. Also presenting will be executives from NeuroSigma, ANEUVO, and Synergia Medical. Venture capital professionals Jeff Chu from Features Capital, Mir Imran from InCube Ventures, and Jeffrey Scott Cohen from Ladenburg Thalmann & Co will participate in a session moderated by JoJo Platt devoted to investment in bioelectronic medicine.

Contributing editor Victor Pikov will moderate a session with executives from three firms in the neuromodulation space for treating obstructive sleep apnea, including market leader Inspire Medical Systems, and challengers Nyxoah and LivaNova.

There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, and JoJo Platt will moderate sessions at the event.

Also at the event, former Axonics CEO Ray Cohen will sit down for a fireside chat with Neurotech Reports Senior Consulting Editor Jeremy Koff for a discussion on the bowel and bladder neuromodulation market.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor. Osypka and Black Swan IP are Bronze Sponsors.

“Bioelectronic medicine merges some of the best attributes of biopharma and neurotech approaches to treating systemic disorders,” said James Cavuoto, editor and publisher at Neurotech Reports. “This eighth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry.”

For more information on the 2025 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

IMAGE link for media: https://www.Send2Press.com/300dpi/25-0317-s2p-LisaShafer-300dpi.jpg

Image caption: Medtech and pharmaceutical industry executive Lisa Shafer, Ph.D., will keynote the 2025 Bioelectronic Medicine Forum in New York City on April 10.

NEWS SOURCE: Neurotech Reports

This press release was issued on behalf of the news source (Neurotech Reports), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/biogen-vp-to-keynote-2025-bioelectronic-medicine-forum-in-nyc/

US Kidney Research Corp Advances Toward Implantable Artificial Kidney

Waterless technology can replace dialysis and transform kidney treatment

ROSEVILLE, Calif., March 13, 2025 (SEND2PRESS NEWSWIRE) — US Kidney Research Corporation (USKRC) is creating the world’s first waterless blood purification device, a pioneering technology with the capability to replace traditional dialysis machines worldwide. A recent groundbreaking discovery in the design of the device’s ion transport system, a critical component responsible for removing excess ions from the bloodstream, restoring ion balance, and directing these excess elements to the urine, is significantly accelerating progress and bringing the device closer to completion.

Image caption: University of Arkansas Lab – Device CAD Image.

The ion transport system plays a vital role in maintaining essential physiological functions. For individuals with kidney disease, the kidneys often fail to filter out excess ions such as sodium, potassium, and phosphorus, causing dangerous imbalances that can lead to serious health issues.

Reaching this milestone brings US Kidney Research Corporation closer to its ultimate goal of developing an implantable artificial kidney. A waterless device is crucial for the development of an implantable artificial kidney. Dialysis’s reliance on a constant water and dialysate supply makes miniaturization and implantation within the body impossible.

This achievement marks a historic milestone as the first successful development of a waterless ion transport system for a medical blood purification device, something that has never been accomplished before.

CEO Roland Ludlow stated, “Creating an ion transport system is an extremely complex scientific challenge. After years of research and extensive experimentation, our scientists have discovered the method needed to complete the task. Breaking through this barrier is a major leap forward.”

Waterless Advantages: In contrast to traditional dialysis systems that depend on water, disposable components like dialyzers and dialysate solutions, as well as a separate water purification infrastructure, the waterless blood purifying device eliminates the need for these costly items, offering significant savings for healthcare providers. Additionally, the device will incorporate innovative technology, such as real-time patient monitoring and precise control over electrolyte, urea, and fluid removal, ensuring greater accuracy and better outcomes for patients.

Ecological Benefits: The waterless blood purifying device addresses environmental challenges by reducing the carbon footprint. It will greatly reduce the billions of gallons of contaminated water generated by dialysis, minimize dialyzer plastic waste, and lower transport and energy costs associated with production.

MISSION & GOALS

US Kidney Research Corporation is dedicated to:

Completing its flagship waterless blood purifying device to replace outdated dialysis machines.
Developing an implantable artificial kidney using the same waterless technology.
Progressing several related renal care products currently in development.

EXPERT COLLABORATION

US Kidney Research Corporation’s innovations are backed by a distinguished research team from the University of Arkansas (UA) and Dr. Ira Kurtz, the Chief of Nephrology at UCLA, who serves as the Corporation’s science/medical advisor and active board member. Dr. Kurtz, a leading expert in kidney disease, works alongside Dr. Jamie Hestekin and the UA team to drive progress toward a viable, long-term solution for kidney disease patients.

ABOUT US:

US Kidney Research Corporation (USKRC) is at the forefront of artificial kidney research and development. Acknowledged by leading organizations such as the American Society of Nephrology (ASN), KidneyX, and the US Department of Health and Human Services (HHS), USKRC is transforming the future of kidney care. By pioneering new standards in treatment, USKRC is bringing hope for a future beyond dialysis. Established in 2015, USKRC is registered as a C-Corporation in Delaware.

Learn more: https://www.uskidneyresearchcorp.com/

MEDIA CONTACT:
Roland Ludlow
US Kidney Research Corporation
EMAIL: contact@uskidneyresearchcorp.com
PHONE: 1-800-674-8904

NEWS SOURCE: US Kidney Research Corporation

This press release was issued on behalf of the news source (US Kidney Research Corporation), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/us-kidney-research-corp-advances-toward-implantable-artificial-kidney/

Divergent CRO Announces Launch of New Contract Research Organization

ATLANTA, Ga. /ScoopCloud/ -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

Related link: https://divergentcro.com/

Silicon Valley High School Senior Works to Improve Cystic Fibrosis Research through AI

SAN FRANCISCO, Calif. /ScoopCloud/ -- Manasvi Pinnaka is a senior at BASIS Independent Silicon Valley in San Jose, CA. She's also the founder and CEO of Nysha.ai, a nationally-recognized nonprofit organization committed to raising awareness for cystic fibrosis.

For the past few years, Pinnaka has worked on numerous projects at the intersection of AI/ML and healthcare, including the detection of disease severity in cystic fibrosis patients using the lung microbiome. Ultimately, with Nysha.ai, she enjoys sharing her passion for biotechnology research while working to improve the standard of care for those with cystic fibrosis.

Pinnaka's goals are to create awareness about this disease in all races and ethnicities while empowering and educating students to explore the world of AI research to advance the finding of a cure for the disease. She's committed to fostering a passion for technology and innovation among young minds.

The nonprofit's advisory board includes Dr. Carlos Milla, professor at Stanford University; Dr. Beate Illek, professor at UCSF; and Dr. Jonathan Widdicombe, emeritus professor at UC Davis. Since its founding, Nysha has organized various research projects, including AI research and literature reviews, relating to cystic fibrosis and its complications with ongoing support from this board and from medical/engineering students. It's also offered more than $200,000 worth of in-kind mentorship services.

"Our volunteers are at the heart of all we do and we're committed to expanding nationally and internationally," Pinnaka says. "We're creating new chapters and working to grow every day."

At Nysha.ai, volunteers have the opportunity to organize presentations at various venues in their communities to raise awareness for cystic fibrosis. These presentations have reached more than 52,000 community members and have raised more than $27,000.

Other initiatives include partnerships with libraries across the world to distribute information about cystic fibrosis to visiting children and their families.

"Our volunteers have also made it possible to bring awareness to schools in their area and some have even started their own clubs that focus on awareness for rare diseases like cystic fibrosis," Pinnaka explains. "It's an exciting time."

Most recently, Pinnaka led Nysha's volunteers in cultivating the next generation of AI technologists, innovators and leaders at a one-day conference - the Youth AI Summit at Capital One Hall. More than 300 high school students, mostly from underrepresented backgrounds, attended and had unique opportunities to engage with AI experts from various fields. There was even a chance to enter into an AI Ideathon pitch competition.

The summit included notable speakers such as Christos Makridis, an economic advisor of the White House; Steven Wellner, associate judge superior court of the District of Columbia; and Dominic Delmolino, vice president of Amazon Web Services. Nysha.ai also delivered speakers such as Dr. Tushar Desai, a professor at Stanford University; and Dr. Steven Jonas, an associate professor at UCLA, to talk about the latest advancements in cystic fibrosis research.

"My primary goals are to encourage testing for cystic fibrosis in underdiagnosed communities, to encourage STEM education among today's youth and to ultimately help to further research projects focused on finding a cure for the disease," Pinnaka says. "To do this, we need to continue to grow our volunteer base."

Interested volunteers can learn more here: https://nysha.ai/

Manasvi Pinnaka is a senior at BASIS Independent Silicon Valley in San Jose, CA. She's also the founder and CEO of Nysha.ai, a nationally-recognized nonprofit organization committed to raising awareness for cystic fibrosis. Pinnaka's goals are to create awareness about this disease in all races and ethnicities while empowering and educating students to explore the world of AI research to advance the finding of a cure for the disease.

Related link: https://nysha.ai/

US Kidney Research Corp Unveils Breakthrough Ultrafilter Membrane for Dialysis

ROSEVILLE, Calif. /ScoopCloud/ -- US Kidney Research Corporation (USKRC) is delighted to announce new groundbreaking research as part of a contract with the University of Arkansas (U of A) resulting in the development of an ultrafiltration membrane with diverse filtering applications for medical and non-medical devices. This remarkable membrane represents a significant advancement, particularly in the field of dialyzers, the filtration device used in hemodialysis machines to remove toxins, promising improved dialysis performance and enhanced ultrafiltration flux.

The recently published research in Scientific Reports (https://www.nature.com/articles/s41598-023-37765-y) unveils a novel membrane created through a tempo cellulosic oxidation process and cast using ionic liquids. Notably, the membrane showcases exceptional biocompatibility, the ability to clear potential uremic toxins, and excellent stability. Its unique structure, characterized by the alignment of fibers after casting, leads to an extraordinarily high flux and substantial BSA rejection in ultrafiltration mode, surpassing the performance of traditional dialysis membranes.

"We were highly impressed by the membrane's behavior and performance; the fiber alignment in the final structure allows for superior functionality compared to conventional dialysis membranes," expressed Jamie Hestekin, one of the lead researchers at U of A.

As part of this concerted effort, USKRC has secured worldwide rights for the patented U of A membrane in all biomedical applications. USKRC's founder and CEO Roland Ludlow, revealed that the corporation intends to explore sublicensing partnerships both domestically and internationally, with the aim of expediting the introduction of this cutting-edge membrane technology to the market, enabling its use in dialysis and other relevant applications.

Dr. Ira Kurtz, Chief of Nephrology at UCLA, who is an author on the Scientific Reports paper and serves as the lead medical/scientific advisor to USKRC commented, "This new membrane chemistry could be a game changer in the care of renal patients."

USKRC is actively engaged in several other research projects, including the development of a waterless portable blood purifying device that could potentially replace current dialysis machines, an implantable artificial kidney, and a coating to prevent blood coagulation within medical device tubing and catheters. The company has solidified its position as a leader in renal therapy research, earning prestigious recognition as a two-time winner of the KidneyX contest, sponsored by the American Society of Nephrology and the US Department of Health and Human Services. Monetary awards for KidneyX were generously provided by the US Congress and the American Society of Nephrology.

About US Kidney Research Corporation:

US Kidney Research Corporation (formerly Curion Research Corporation), is an award-winning company incorporated in Delaware (C-Corp), founded in June, 2015. The company is creating the world's first waterless blood purification technology for use in a portable device and ultimately an implantable artificial kidney, as well as other novel technologies to improve the lives of patients with end stage renal disease (ESRD) or acute kidney injury (AKI). US Kidney Research Corporation has patents for its waterless blood purifying technology in USA, Japan, India, S. Korea, China, along with 17 European Unitary patent member countries.

More information: https://www.uskidneyresearchcorp.com/

US Kidney Research Corporation (USKRC) is delighted to announce new groundbreaking research as part of a contract with the University of Arkansas (U of A) resulting in the development of an ultrafiltration membrane with diverse filtering applications for medical and non-medical devices.

Related link: https://www.uskidneyresearchcorp.com/

The Pap Corps Makes Historic $8.4 Million Donation for Cancer Research – Sylvester Comprehensive Cancer Center to Benefit from Nonprofit’s Largest Gift

DEERFIELD BEACH, Fla. /ScoopCloud/ -- The Pap Corps Champions for Cancer Research (thepapcorps.org) recently presented a historic donation to Sylvester Comprehensive Cancer Center of $8.4 million. This gift came in two parts, $3.4 million through the volunteers' fundraising efforts and $5 million from an anonymous donor. This is the largest single gift in the nonprofit's 70-year history. The Pap Corps supports research for all types of cancer at Sylvester and has over 20,000 volunteer members in Palm Beach, Broward and Miami-Dade Counties.

"We are thrilled to make this unprecedented gift to Sylvester," said Sally Berenzweig, CEO of The Pap Corps. "Thanks to the tremendous efforts of our members and the incredible generosity of our anonymous donor, this gift will be used to support groundbreaking research that results in lifesaving treatments for cancer patients."

During the check presentation event, which took place at Boca West Country Club, Dr. Antonio Iavarone, the deputy director of Sylvester and a renowned expert in glioblastoma and other aggressive brain tumors, spoke to the over 400 members in attendance about the outstanding advances that are occurring thanks to cancer research. During his presentation, he acknowledged the incomparable support of The Pap Corps members and thanked them for their untiring dedication.

"Today was one of the most exciting days in the history of The Pap Corps," said Susan Dinter, Chair. "We are so grateful for the remarkable support of our members, who work tirelessly year after year to fund these multimillion-dollar donations, and to our benevolent donor whose commitment to our mission inspires us all! For 70 years, we have supported cancer research and will continue to do so until a cure can be found."

June is National Cancer Survivor Month and thanks to incredible advances during the past decades, death rates have declined, but The Pap Corps' job is far from over. The members of this organization know that revolutionary new treatments are on the horizon, but funding is critical to reach the next level of success. Achieving greater survival rates, year after year, is what keeps the organizations' over 20,000 members motivated!

To join The Pap Corps, learn more at: https://www.thepapcorps.org/.

About The Pap Corps:

Since its founding in 1952, The Pap Corps, a 501(c)(3), has donated more than $110 million to Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, including a historic $50 million pledge in 2016. The Pap Corps derives its name from Dr. George Papanicolaou, a pioneer in cytopathology and early cancer detection, who introduced the world to the revolutionary 'Pap' test. A small group of women began the organization to support his efforts, and over the decades it has grown into an organization of over 20,000 men and women, in over 50 chapters, raising funds to support research for all types of cancers.

About Sylvester Comprehensive Cancer Center:

Sylvester Comprehensive Cancer Center, part of UHealth - University of Miami Health System and the University of Miami Miller School of Medicine, is the only National Cancer Institute (NCI) designated and nationally ranked cancer center in South Florida. NCI designation recognizes that Sylvester has met the most rigorous standards for cancer research, beginning in our laboratories, extending to patient care, and meeting specific needs in our community. Sylvester is known as South Florida's leader in patient-focused cancer research and care, offering the only Phase 1 Clinical Trials program - the first step in evaluating how patients respond to the latest investigational treatments.

NCI designation further expands Sylvester's ability to provide access to novel therapies through more clinical trials and collaboration with other designated centers. Equipped with a highly qualified team of more than 2,400 cancer-focused physicians, researchers and support staff working together, Sylvester discovers, develops, and delivers more precision cancer care. To serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities throughout South Florida.

The Pap Corps Champions for Cancer Research (thepapcorps.org) recently presented a historic donation to Sylvester Comprehensive Cancer Center of $8.4 million. This gift came in two parts, $3.4 million through the volunteers' fundraising efforts and $5 million from an anonymous donor. This is the largest single gift in the nonprofit's 70-year history.

Related link: https://www.thepapcorps.org/

Award-winning universal vaccine method calls for deeper scientific exploration – The Slammer Method

CHESAPEAKE, Va. /ScoopCloud/ -- A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.

As the name denotes, The Slammer Method, quite literally places the organism into "The Slammer" and crushes it through powerful force. The method entails using a series of approaches to dismantle the organism and prepare it for the body's immune system.

It's a new and inspirational method which uses the concepts of physics, biologics and natural extremes to combat an ever-changing environment of infectious diseases.

While the method is rudimentary in design, it's through its simplicity that great things are achievable. It all starts with a container that's capable of withstanding vast amounts of pressure and then subjecting an organism to multiple tests. In turn, these tests will determine how to proceed should the organism cease to function with pressure alone. After that, the next steps can happen which include adding the chemical equivalent of the enzyme or MPO used by the white blood cell to break down the organism.

Medical research will be able to verify that the organism is unable to feed or reproduce and The Slammer Method can be used for all infectious diseases, including HIV. It's derived from several factors in nature and has untapped possibilities.

"The potential to save countless lives is very real," Kikkert says. "It should be seriously explored through modern science, medical research and technological engineering."

Read the complete article: https://www.hilarispublisher.com/open-access/how-to-create-effective-vaccines-93437.html

View the transcript of the presentation in London: https://www.allforyou2020.org/post/how-to-create-effective-vaccines

About Eric Kikkert:

Eric Kikkert has expertise in mechanical engineering and physics. He has a deep understanding of quantum relativity, quantum structures and mechanics and has produced advanced mathematical methods and concepts to create new formulas which permit unification of physics and relativity. It's here that he commits his understandings to biology to reverse engineer the quantum structure with particle physics.

MEDIA CONTACT:
Eric Kikkert, +1-757-949-8864, email: KikkertEric[at]icloud.com

A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.

The Pap Corps Celebrates 70 Years of Funding Research for All Types of Cancer

DEERFIELD BEACH, Fla. /ScoopCloud/ -- The Pap Corps Champions for Cancer Research will celebrate its 70th anniversary with a beautiful luncheon event at the Polo Club in Boca Raton on Tuesday, November 15, 2022. During the past seven decades, the nonprofit has grown from a small group of women supporting the pioneering work of Dr. George Papanicolaou to a dynamic organization with over 20,000 members, who fund research for all types of cancer at Sylvester Comprehensive Cancer Center.

The event, hosted by Michael Williams of WPTV, will pay tribute to the organization's impressive history and will honor two special guests, major donor Gerald Yass and Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center.

For more information visit https://www.thepapcorps.org/.

"The Pap Corps has made an incredible impact on the lives of countless people during these seven decades," said Sally Berenzweig, CEO. "Without funding for cancer research, we wouldn't have the groundbreaking, life-saving treatments that have allowed so many to make the journey from patient to survivor. As a community, we owe a tremendous gratitude to all The Pap Corps members who devoted their time and money to supporting the mission of a world without cancer."

During the event, The Pap Corps will showcase many of these dedicated members in video collage and will honor the past presidents who shaped and guided the organization's tremendous growth during the past 30 years.

"Thanks to our past presidents, incredible directors, and dedicated members, we have many triumphs to celebrate," said Chair Susan Dinter. "And so many of the cherished memories we've created transcend the big check moments and go directly to the heart of our organization. The Pap Corps is special not only because of what we do, but who we are. The enduring friendships within the Corps have created a bond that makes our organization the force it is today. And that is something we are all very proud of!"

The Pap Corps is thankful for the many sponsors who are supporting this event including The Harcourt M. and Virginia W. Sylvester Foundation; Sylvester Comprehensive Cancer Center, University of Miami Health System; the Wrobel Family Foundation, L'Oréal Paris; Susan& Ed Dinter, Linda & Joel Moses, Judith Harold; the Wechsler Foundation; Sharon Goodhart Travel Agency; Alan Joyce of Raymond James; Heidi S. Schaeffer, M.D. Charitable Trust; GL Homes; PNC; Bauman Medical; Opal Grand Oceanfront Resort & Spa; Nothing Bundt Cakes; Searcy Law; Daszkal Bolton; AmFund; Hotwire Communications; Madeline Wolfson; Southern Glazer's Wine & Spirits, and media sponsor Boca Magazine.

About The Pap Corps:

Since its founding in 1952, The Pap Corps, a 501(c)(3), has donated more than $110 million to Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, including a historic $50 million pledge in 2016. The Pap Corps derives its name from Dr. George Papanicolaou, a pioneer in cytopathology and early cancer detection, who introduced the world to the revolutionary 'Pap' test. A small group of women began the organization to support his efforts, and over the decades it has grown into an organization of over 20,000 men and women, in over 50 chapters, who raise funds to support research for all types of cancers.

The Pap Corps Champions for Cancer Research will celebrate its 70th anniversary with a beautiful luncheon event at the Polo Club in Boca Raton on Tuesday, November 15, 2022. During the past seven decades, the nonprofit has grown from a small group of women supporting the pioneering work of Dr. George Papanicolaou to a dynamic organization with over 20,000 members, who fund research for all types of cancer at Sylvester Comprehensive Cancer Center.

Related link: https://www.thepapcorps.org/

Tens of Thousands of Researchers Celebrated During 13th National Postdoc Appreciation Week

ROCKVILLE, Md. /ScoopCloud/ -- The National Postdoctoral Association (NPA) today kicked off the 13th annual National Postdoc Appreciation Week (NPAW), taking place today through Friday. NPAW is the nation's largest celebration of postdoctoral scholars who serve at more than 300 institutions, acknowledging the significant contributions "postdocs" make to research, innovation and scientific discovery. This year's NPAW theme, "Finding Your Balance," recognizes the challenges postdocs face in balancing the rigors of their research positions with maintaining their health and wellness.

Postdocs are individuals holding doctoral degrees engaged in a temporary period of mentored research or scholarly training to gain needed skills to excel in their careers. These scholars conduct a large share of critical, cutting-edge research across all disciplines at universities, research institutions and industry members across the United States.

"Postdocs require exemplary discipline, focus, and balance to succeed in their challenging positions," said Tom Kimbis, J.D., executive director and chief executive officer of the NPA. "They are the backbone of science and research leadership in our country and deserve recognition throughout the year. Carving out a week to celebrate their remarkable work ethic and achievements is the least we can do."

The contribution of the roughly 70,000 U.S. postdocs, whose numbers are concentrated in the STEM fields and are instrumental to much of the early-stage research that occurs throughout the country, is often overlooked, as the academic postdoc is neither a student nor a faculty member. Yet, postdocs represent the highest-educated individuals in our society and drive innovation daily.

"Many don't realize that thousands of postdocs work in the social sciences - from economics to psychology - and go onto leadership positions in government, industry, and non-profit organizations," commented Stephanie Eberle, M.Ed., executive director of BioSci Careers at Stanford University. "Like those in the physical sciences, their roles are critical to societal growth and innovation."

Since its founding by the NPA in 2009, NPAW has grown into a truly national event, with universities, medical centers, industry members, and others hosting events this week to acknowledge the contributions of postdocs. Popular events during NPAW include professional and career development workshops, networking activities, and social events celebrating the immense contribution of postdocs to our nation's thought leadership. This year, roughly 40 free national events are open to all postdocs, in addition to local events happening on campuses across the nation.

NPAW 2022 is anchored by a kickoff event with opening remarks by Sharon Milgram, Ph.D., director of the Office of Intramural Training & Education (OITE) at the National Institutes of Health (NIH), and a panel discussion, featuring Robert Hable, Ph.D., innovation and product commercialization coordinator at BASF; Inge Hansen, Psy.D., clinical psychologist and director of well-being at Stanford University; and Yen Teng Tai, Ph.D., postdoctoral researcher at Penn State University College of Medicine. The discussion will focus on challenges early career researchers face, lessons learned from their own struggles, and a framework for postdocs to build better balance in their professional lives as they navigate their career progression.

A calendar of 2022 NPAW events can be found at https://www.nationalpostdoc.org/page/2022NPAW

This year, NPAW is made possible by NPA Distinguished Partner, Gallagher Insurance, and NPA Gold Partner, Proteintech.

The NPA is a national charitable and educational non-profit association headquartered in Rockville, Maryland, that seeks to improve the postdoctoral experience by supporting a culture of inclusive connection. At the individual, organizational, and national levels, the NPA facilitates enhanced professional growth, raises awareness, and collaborates with stakeholders in the postdoctoral community. Membership in the NPA is open to all organizations and individuals interested in advancing the interests of postdocs in the United States.

Affiliate membership in the NPA for most postdocs is free and available at https://www.nationalpostdoc.org/.

To support NPA and its charitable mission to assist postdocs, please visit https://www.nationalpostdoc.org/page/donate or text NPAW2022 to 44-321.

The National Postdoctoral Association (NPA) today kicked off the 13th annual National Postdoc Appreciation Week (NPAW), taking place today through Friday. NPAW is the nation's largest celebration of postdoctoral scholars who serve at more than 300 institutions, acknowledging the significant contributions "postdocs" make to research, innovation and scientific discovery.

Related link: https://www.nationalpostdoc.org/

Proteios Technology, Inc. Awarded $1.6 Million NIH SBIR Grant to Commercialize its Multivariate Cell Isolation Technology

SEATTLE, Wash. /ScoopCloud/ -- Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Cell biology is complex. And conducting experiments on an isolated population of cells, rather than a heterogeneous mix, is a common approach to reduce experimental complexity. Cell isolation allows cell biologists to confidently attribute observed effects and responses to a particular cell type.

Specifically, Proteios' multivariate cell isolation technology provides high-performance, antibody- and magnetic bead-free isolation of cell types in fewer than 30 minutes. This is a big reduction in time compared to currently available methods, while meeting or exceeding cell yield, purity and viability.

Proprietary Proteios Chimeras will be designed and developed to bind to each of the 20 target cell types with high specificity and selectivity through a combination of robotic biological screening, Machine Learning (ML) and Molecular Dynamics (MD) simulation.

Proteios will also incorporate Proteios Chimeras into its cGMP cell therapy manufacturing device - a bench prototype funded under contract by the National Cancer Institute (NCI). The device provides end-to-end manufacturing of cell therapies in a closed and fully-automated system with concise control over the multiple cell types that form the basis of cell therapy formulations. Proteios Chimeras will be a major component of consumables for the cGMP cell therapy manufacturing device.

"It's believed that the effectiveness of cellular therapeutics can be improved by the addition/removal of certain secondary cell types," Bob Snyder, Ph.D., co-founder and CEO of Proteios Technology, says. "Proteios' cell isolation technology will provide for the parallel enrichment and/or depletion of any cell type as new cell therapy formulations are investigated, reducing the vein-to-vein time and overall manufacturing cost."

Proteios is also preparing for the immediate commercial release of its research-scale recombinant protein purification kits which will provide a viable alternative to His Tag technology, unusable with about 20 percent of proteins of interest.

Initially, Proteios will launch two kits based on a proprietary affinity tag and a silica-based resin for:

1 - high-expressing proteins; and

2 - low-expressing proteins.

To learn more: https://www.proteios.com/

About Proteios Technology:

Proteios Technology is a leading provider of products and services dedicated to supporting the discovery of advanced therapeutics and their efficient manufacturing. Its innovative solutions support research at all levels from discovery and translational research to cGMP manufacturing and companion diagnostics. Its technologies enable the multivariate (parallel), tag-free isolation of any biological, including proteins/biopharmaceuticals, cell types, antibodies and viruses. Proteios' research-scale kits enable the discovery of new advanced therapeutics. And the inherent scalability of the technology allows the same methodology to be used in the manufacturing of advanced therapeutics and dramatically reduces the time required for process development.

Proteios is driven by the goal to lower the cost of healthcare and to provide advanced therapeutics to a larger patient population. It's located in the heart of Seattle and adjacent to some of the world's leading cell therapy research institutes - including the Fred Hutchinson Cancer Research Center, Seattle Children's Research Institute and the Seattle Cancer Care Alliance.

Proteios Technology, Inc. is pleased to announce it's received a $1.6 million SBIR Phase II grant from the National Institutes of Health (NIH) to commercialize its multivariate (parallel) cell isolation technology. Grant funds will be used to extend Proteios' cell isolation kits to include up to 20 of the most common cell types currently used in cell therapy development.

Related link: https://www.proteios.com/

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. /ScoopCloud/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Related link: https://vyriad.com/

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. /ScoopCloud/ -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

Related link: https://puremhc.com/

Neurosoft Bioelectronics Receives Nearly $3 Million in Funding

NEW YORK, N.Y. /ScoopCloud/ -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant. Additionally, the firm secured a $100,000 convertible note from the Fongit Innovation Fund.

Proceeds will fund continued development of the company's soft flexible electrodes to be marketed as SOFT ECoG™, a family of implantable devices which can seamlessly interface with the brain. The novel devices are up to 1000x softer and 2x thinner than clinical electrodes, with integrated electrode sites up to 100x smaller, making them suited for high-resolution recording and stimulation of the brain for up to thirty days. Their conformability and softness make them ideally suited for placement in the sulci of the brain - hard to reach areas of the brain where many disorders may best be treated. The deep folds of a sulcus are inaccessible for other electrodes while SOFT ECoG can be safely and precisely placed for stimulation and recording.

"Given that 70% of the surface of the brain is buried in sulci, it was critical to develop a technology that could safely and effectively work in those spaces," said Neurosoft Bioelectronics' CEO, Nicolas Vachicouras, Ph.D. "We're eager to put these significant funds toward clinical testing and regulatory approval of SOFT ECoG in the upcoming months, which will simultaneously drive progress of SOFT TINNIT. Together, these products have the potential to bring relief to epilepsy, brain tumor, and tinnitus patients, and in the future will impact those living with other neurological disorders such as deafness, blindness, tetraplegia, and chronic pain."

Vachicouras will present an update about the company and technology at the Bioelectronic Medicine Forum in New York today.

Most of the funds are designated for the further development of SOFT ECoG however, the innovations made will simultaneously advance the company's second product, SOFT TINNIT™. SOFT TINNIT is a chronic implant to perform closed-loop neuromodulation of the cortex to provide relief for patients suffering from severe tinnitus. Severe tinnitus, which has no cure, affects more than 7 million people in the U.S. and Europe.

Learn more: https://www.neurosoft-bio.com/technology

About Neurosoft Bioelectronics

Neurosoft Bioelectronics Ltd. is a Swiss medtech spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL). Neurosoft Bioelectronics develops next generation soft implantable electrodes to interface with the brain for the treatment of severe neurological disorders. Its main product is a fully implantable closed-loop Brain-Computer Interface (BCI) to treat severe tinnitus, a condition that affects 7M people in the US and Europe, of which 7% attempt suicide every year. It is also developing a family of subdural electrodes intended for monitoring during brain tumor and epilepsy resection surgery.

Learn more at: https://www.neurosoft-bio.com/

RELATED LINKS:

https://neurotechreports.com/pages/bioelectronic-medicine-forum.html

Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant.

Related link: https://www.neurosoft-bio.com/

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

The research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.

"This collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification," Dr. Bestard stated.

"Today, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management," said Dr. Buchli.

Steve Mayer MD, Chief Medical Officer at PTS stated, "We're very excited about the potential of this technology because it allows a very early diagnostic view of an individual's risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its ecommerce website, https://www.hlaprotein.com/, Pure Protein offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Vall d'Hebron Barcelona Hospital Campus

We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management. The Vall d'Hebron Barcelona Hospital Campus is the combination of our five entities: the Vall d'Hebron University Hospital, the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron Oncology Institute (VHIO), the Multiple Sclerosis Center of Catalonia (CEMCAT) and the Autonomous University of Barcelona.

We are constantly in touch with patients; our starting point is the challenges they present in our day-to-day work to continue to innovate and find new diagnostic methods and treatments. The talented team that has made us a leading institution allows us to work towards attracting excellence and training the best professionals in clinical practice.

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

Related link: https://www.puretransplant.com/

November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

The Conference registration was complimentary this year. To learn more about this extraordinary conference, guest speakers, and the diverse topics presented visit: https://www.cdiff2021.com

For conference coverage visit ContagionLive Infectious Diseases Today: https://www.contagionlive.com/latest-conference

On behalf of the C Diff Foundation, Sahil Khanna, M.B.B.S, M.S. proudly presented the Lifetime Achievement Award to Dale Gerding, MD, MACP, FIDSA, FSHEA for his outstanding vision, dedication, and commitment and for the advancement of Clostridioides difficile research, development, and care through the years. The Dale Gerding Lifetime Achievement award will be presented annually during the C Diff Foundation's November conference to a healthcare professional meeting the criteria, nominated by peers, and awarded by Dr. Gerding himself.

The C Diff Foundation "Making a Difference: Innovations in Infection Prevention" 2021 award was presented to PhoneSoap acknowledging their exceptional organization who is making a difference in the Infection Prevention community, with their innovative products, services, and technologies.

The award was accepted by Wes LaPorte, CEO of PhoneSoap. "PhoneSoap's mission has always been to limit the spread of infectious diseases through science and technology. We are honored to accept the Innovations in Infection Prevention award of 2021 from the C Diff Foundation given their very important endeavor to bring awareness, education, and advocacy globally," stated LaPorte.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine).

Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to all the Sponsors and Keynote speakers for their generous support of the 9th Annual International C. diff. Conference and Health EXPO. Together we deliver superior educational up-to-date data, advance the healthcare professional knowledge and understanding of the topics discussed, and serve as the leading organization educating and advocating for C. difficile infection prevention, treatments, clinical trial, diagnostics, support, and environmental safety worldwide. We are grateful to be the leading resource for patients, families, caregivers, and healthcare professionals.

Many US Governors have signed a state proclamation proclaiming November 2021 as Clostridioides difficile (C. difficile, C. diff.) Infection Awareness Month.

"Our shared goal is to witness a significant increase in C. difficile awareness, with a noted reduction in C. difficile infections worldwide by the year 2025. We would also like to thank Seres Therapeutics, Rebiotix, a Ferring Company, and Ferring Pharmaceuticals for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiff2021 #cdiffawarenessmonth

C Diff Foundation(TM) is a trademark of C Diff Foundation, established 2012 in the U.S.

C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

Related link: https://cdifffoundation.org/

Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium

AUSTIN, Texas /ScoopCloud/ -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

Mr. Drapeau also visited Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy regarding the ongoing multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Dr. Garber will be the primary contact in Europe for STEMREGEN®.

"We are delighted that we will now be able to offer STEMREGEN to the people of Spain. The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the spring of 2022, aims to evaluate the effect of ESCM in cases of heart failure. Study participants will be evaluated over several months, at which times their NYHA functional classification and echocardiographic parameters will be assessed.

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our website: https://www.kalyagen.com/.

About Miguel Garber

Miguel Garber over 32 years experience in Internal medicine and cardiology, with expertise in regenerative medicine, training and education, research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Española de Medicina Regenerativa y Terapia Celular. Dr. Garber can be reached at mggarber@gmail.com.

CONTACT:

Biomics, LLC (dba Kalyagen™)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

Related link: https://www.kalyagen.com/

Gala to end Pancreatic Cancer Raises Over $1 Million

ATLANTA, Ga. /ScoopCloud/ -- Purple Pansies, a pancreatic cancer nonprofit organization, recently held its 12th annual Pillars of Hope Gala, presented by Kroger, raising more than $1 million in one evening. The gala was officially renamed Pillars of Hope by the nonprofit to show support for survivors and the hope to cure pancreatic cancer.

Founding Purple Pansies in 2008, Maria Fundora holds the gala in September in honor of when she lost her mother, Iluminada Milian, in 2007. "She fought so hard," Fundora said. "When I lost her three months after diagnosis I could not just sit still. I had to do something. I had to fight, to be able to find a way to help others, so others would not go through what my family went through."

The evening included a presentation of the inaugural Pillars of Hope Bill Palmer Legacy Award.

The award honors the late Bill Palmer (founder of Applebee's) for his pioneering support of Purple Pansies and his own courageous fight with the disease. For the first year of this award, Tim Brown, Atlanta President of Kroger, received the award for his involvement and service, both personally and professionally.

"Kroger and our partners are excited to be involved with Purple Pansies and Pillars of Hope and to be able to assist in raising money for this organization. I was truly honored to be recognized and receive the Bill Palmer Legacy Award," said Tim Brown, president of the Kroger Atlanta division. "My wife, Angie, and I look forward to supporting this organization in the future."

According to the American Cancer Society, research for pancreatic cancer is one of the least funded of all cancers. The organization is guided by "CARS": Community, awareness and resources.

To date, Purple Pansies has raised over $4 million to support research and clinical trials through the Phoenix-based Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

"We have learned people are coming in earlier to diagnose pancreatic cancer," said Dr. Daniel Von Hoff, Distinguished Professor in TGen's Molecular Medicine Division. "Stage 1a early pancreas cancer 5 year survival rates have grown from 45% to 84% due to awareness with events like this gala."

During the gala, a video featured Dr. Von Hoff, describing how pancreatic cancer treatments are improving and a current clinical trial of patients on a ketogenic diet. He encouraged the fight and displayed a purple bracelet made by Lana Stowell, a local Alpharetta, Ga., youth. Everyone in the audience received one of the more than 200 bracelets made by Lana to join us together as a community.

Dr. Andrew Page, M.D., director of surgical oncology and HPB surgery at Piedmont Healthcare, spoke about the unique fight of pancreatic patients: "They all share in common their trust in me which I treasure and their warrior spirit which I honor ... Let's keep going."

During the evening, Purple Pansies officially announced the launch of their scholarship program for high school seniors who have a parent, guardian or are themselves suffering from pancreatic cancer. Their goal is to continue support families across the country that have been affected by pancreatic cancer.

Additional information can be found at https://purplepansies.org/

FOLLOW ON SOCIAL AT:

https://www.facebook.com/pplpansies/

https://twitter.com/pplpansies

https://www.instagram.com/pplpansies/

Purple Pansies, a pancreatic cancer nonprofit organization, recently held its 12th annual Pillars of Hope Gala, presented by Kroger, raising more than $1 million in one evening. The gala was officially renamed Pillars of Hope by the nonprofit to show support for survivors and the hope to cure pancreatic cancer.

Related link: https://purplepansies.org/

Drink HRW Hydrogen Tablets Improve Markers of Aging in the Elderly

COQUITIAM, B.C. /ScoopCloud/ -- Aging is a reality that we all deal with, with age-related diseases creating a massive burden on our healthcare system. In recent years, researchers have begun exploring therapeutics that could potentially stave off, or even reverse, some of the deterioration associated with aging. Now, Drink HRW reports that a new randomized, placebo controlled clinical trial that followed elderly participants for 6 months, published online October 1st in Experimental Gerontology, explains that high doses of hydrogen water (HRW), delivered via hydrogen tablets, could be an effective strategy at improving multiple age-related measurements and outcomes in an elderly population.

The randomized, placebo-controlled cross-over trial compared the effects of chronic administration of hydrogen-rich water, created by hydrogen tablets, against baseline conditions and placebo control for numerous markers associated with the aging process in an elderly population (70+). Participants consumed either HRW, or placebo water, for 6 months. HRW lengthened telomeres, whereas the placebo group saw a decrease, improved brain metabolism, lowered subjective reports of pain, improved parameters within the senior fitness test, and led to strong trends regarding improvements in DNA methylation, increased antioxidant activity, and reduced oxidative stress.

Shortening telomeres have been hypothesized as being a causative factor in the aging process. As telomeres shorten, incidence of disease and deterioration increases, and survival outcomes decrease. Additionally, a decline in brain metabolism has been linked to onset of many neurological issues.

Sergej Ostojic, M.D., PH.D., Professor of Medicine at the University of Novi Sad, a senior author of the Experimental Gerontology study said, "We have been investigating hydrogen use in medicine in my lab for over a decade, and we already recognized its potential to improve metabolic health and every-day functioning in elderly. However, this study for the first time demonstrated its potential to improve several molecular and phenotypic biomarkers of aging. It's perhaps too early to say that hydrogen is an anti-aging compound but this study opens a new chapter in hydrogen research and implementation, and emphasizes several pathways linked with hydrogen action in the human body."

Alex Tarnava, Chief Executive Officer of Drink HRW said, "The aging process leads to deterioration and disruption in many of the key functions within our bodies. Molecular hydrogen has shown across 2000 publications and 120+ human studies to play a corrective role in restoring many of these proper functions, such as improving metabolic markers, promoting a healthy inflammatory response, and supporting the delicate harmony between our bodies natural levels of antioxidants and beneficial oxidative stressors. This is an important study that demonstrates the potential or high-dose hydrogen therapy to slow down, or even temporarily reverse, some of the deterioration aging causes."

Tarnava added, "At Drink HRW we deliver the highest dosage and concentration of hydrogen in water instantly available anywhere in the world, and we are committed to supporting research around the world to better understand this important and fascinating molecule. We work with researchers to search for the truth, believing strongly that the researchers, not private companies, should have the sole authority to decide if they will publish results. We believe pursuit of the truth and integrity in research is the best path towards long term growth."

Sergej Ostojic is a senior biomedical scientist with a broad research background in medicine, applied physiology, and nutrition. He is a board-certified M.D. and holds a Ph.D in Medical Sciences. Dr. Ostojic currently works as a full professor of biomedical sciences at the University of Novi Sad, and an adjunct professor at the University of Belgrade School of Medicine. His research expertise and experience include pre-clinical and clinical development of mitochondria-related nutraceuticals and nutritional supplements, tissue-specific metabolic assessment and translation, and work physiology.

He has authored more than 200 scientific papers, 30 book chapters and books, and 5 patent applications, and has been the recipient of internationally competitive research scholarships including a WADA Scientific Research Grant, the NSCA International Award, research grants from the World Health Organization and European Commission, and many industrial endowments.

About Drink HRW

Drink HRW is on a mission to revolutionize the supplement industry with a new, science-based approach. In just 4 years of availability, various research teams have published 9 clinical trials and 4 case studies using their products, with an additional 15+ clinical trials and 4 preclinical research programs underway. Further, the Drink HRW technology is the only molecular hydrogen supplement on the market to obtain New Dietary Ingredient status after filing with the U.S. FDA.

For more information, please visit https://drinkhrw.com/

Aging is a reality that we all deal with, with age-related diseases creating a massive burden on our healthcare system. Now, Drink HRW reports that a new randomized, placebo controlled clinical trial that followed elderly participants for 6 months, published online October 1st in Experimental Gerontology, explains that high doses of hydrogen water (HRW), delivered via hydrogen tablets, could be an effective strategy at improving multiple age-related measurements and outcomes in an elderly population.

Related link: https://drinkhrw.com/

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT. Learn more at: https://www.cdiffwalks.com

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus and the variants of SARS-CoV-2 that have been emerging and circulating around the world throughout the COVID-19 pandemic.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"C Diff Foundation volunteering members have a passion to improve the lives of patients, families, and caregivers who have been impacted by C. diff. infections worldwide," says Nancy C. Caralla, Founding President, Executive Director of the C Diff Foundation. "At the in-person C. diff. Awareness Walks, a safe distance will be maintained, and hand sanitizer will be available to ensure a safe outdoor event. 'Let's Walk' presents educational information shared by health care professionals, and C. diff. Survivors, through on-demand walks and livestream options located on the dedicated event website: https://cdiffwalks.com."

Thank you, Ferring Pharmaceuticals, for being the Global Sponsor of the 5th Annual Global C. diff. Awareness Walks. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information visit https://www.ferringusa.com.

We also extend our thanks to Seres Therapeutics, Inc. for being the Diamond Sponsor of the 5th Annual Global C. diff. Awareness Walks.

Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiffwalks2021 #cdiff2021

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

MEDIA CONTACT:

Kathy Bischoff, Global Walk Committee

kathy@cdifffoundation.org

(727) 205-3922

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0920s2p-cdf-events-300dpi.jpg

C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT.

Related link: https://cdifffoundation.org/

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital.

Related link: https://www.puretransplant.com/

Mouth bacteria could make stronger vaccines

HAMPTON, N.J. /ScoopCloud/ -- Three researchers have published a groundbreaking paper https://www.nature.com/articles/s41541-021-00341-4 on the importance of oral bacteria in the fight against infectious diseases like influenza, HIV, and COVID-19, Gingivax LLC announced today.

The bacteria in our mouths have traditionally been recognized as a nuisance or worse. They are the cause of tooth decay, gingivitis, and periodontitis. Since we were kids, we were taught to vigilantly brush our teeth twice a day to keep them healthy.

But it turns out that oral bacteria also contain a secret: Research indicates that they possess the tools necessary to boost our immune systems against nastier pathogens, like the coronavirus. The new paper, published in the prestigious journal NPJ Vaccines, suggests that we can exploit these bacteria by using bits and pieces of them in vaccines.

Vaccines work by stimulating an immune response, specifically the part of the immune system responsible for producing antibodies. Small molecules called adjuvants are typically added to vaccines to make them more potent and, hence, elicit a stronger immune response.

Unfortunately, the "gold standard" of adjuvants - an aluminum salt called alum - is no longer seen as adequate because it does not activate all of the necessary components of the immune system to elicit a robust mucosal antibody response. Specifically, it does not activate Th17 cells, which play a central role in the production of antibodies in mucosal surfaces, such as those found in our mouths and noses. (Protecting these surfaces is key to stopping infectious respiratory diseases like influenza and COVID.)

Worse, there has been little progress over the last few decades in the development of new adjuvants, largely a result of the steep regulatory hurdles required for approval.

Until new adjuvants are developed, vaccine technology will be severely limited.

That is why Gingivax, a new company centered around the benefits of the oral microbiome, is investigating oral bacteria as a potential source of new adjuvants. Molecules extracted from these bacteria, which can activate crucial Th17 cells, could be added to vaccines to increase their efficacy.

This isn't the first time that bacterial components have been investigated as potential adjuvants. Previous research examined the use of gut bacteria, but the adjuvants derived from them can cause serious adverse events in patients. Because safety is the top concern in vaccine development, an alternative path is needed.

That is why we have turned to oral bacteria. Research indicates that the adjuvants derived from them can activate the immune response without overstimulating it and triggering adverse events.

Gingivax is currently seeking grants to conduct research in the development of novel adjuvants.

Learn more: http://www.gingivax.com/

Contact info:
Gingivax LLC
Name Marcelo Freire
Email Marcelo@gingivax.com

Three researchers have published a groundbreaking paper on the importance of oral bacteria in the fight against infectious diseases like influenza, HIV, and COVID-19, Gingivax LLC announced today.

Related link: http://www.gingivax.com/

The Pap Corps Donates $2 Million to Sylvester Comprehensive Cancer Center

DEERIELD BEACH, Fla. /ScoopCloud/ -- Overcoming the numerous obstacles imposed by the pandemic, The Pap Corps Champions for Cancer Research displayed their indomitable spirit during their May Presidents Zoom meeting when they announced a $2 million donation to Sylvester Comprehensive Cancer Center. The nonprofit has made numerous multimillion dollar donations to support research at South Florida's only NCI Designated cancer center; however, this year's gift required tremendous determination and innovative fundraising.

"I cannot tell you how grateful I am for the way our board and our 20,000 members rallied during these difficult times," said Susan Dinter, chair of The Pap Corps. "While COVID-19 stopped many things, it did not stop cancer or our members! I am so proud of the incredible resourcefulness of our wonderful volunteers and am thrilled that during National Cancer Research Month we were able to make this substantial donation."

Pap Corps members, throughout all 50 chapters, created virtual versions of their usual fundraisers and also developed new strategies, events and campaigns to raise money. In addition, the launch of the Giving Train monthly donation program, brick and bench sales at The Garden of Hope in Deerfield Beach and the growth of events in Palm Beach helped the organization develop new paths for fundraising.

During the Zoom meeting, Dr. Stephen Nimer, Director of Sylvester Comprehensive Cancer Center spoke to the members and thanked them for their commitment and generosity.

"While we were unable to gather in person for this check presentation, I know everyone felt a tremendous sense of accomplishment," stated Sally Berenzweig, who assumed the role of CEO in January 2021. "Working with these incredible volunteers during the past months has truly been an inspiration, and I look forward to what we will achieve during the months ahead."

ABOUT THE PAP CORPS

Since its founding in 1952, The Pap Corps has donated more than $110 million to Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, including a historic $50 million pledge in 2016 dedicating The Pap Corps Campus at Sylvester in Deerfield Beach. The Pap Corps derives its name from Dr. George Papanicolaou, a pioneer in cytopathology and early cancer detection, who introduced the world to the revolutionary 'Pap' test. A small group of women began the organization to support his efforts, and over the decades it has grown into an organization of over 20,000 men and women, in over 50 chapters, who raise funds to support all types of cancers.

Learn more: https://www.thepapcorps.org/

Media Contact:
Kay Renz
Kay@KRPRMediagroup.com

Overcoming the numerous obstacles imposed by the pandemic, The Pap Corps Champions for Cancer Research displayed their indomitable spirit during their May Presidents Zoom meeting when they announced a $2 million donation to Sylvester Comprehensive Cancer Center.

Related link: http://www.papcorps.org/

Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx

AUSTIN, Texas /ScoopCloud/ -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Pure MHC Solutions will provide collaborators access to Pure MHC's unique tools, experience, intellectual property, and infrastructure in HLA peptide target discovery, presentation, validation, and related competencies in a discrete, project-based manner. Pure MHC's core technologies are broadly applicable for oncology, autoimmune, and infectious disease indications.

Using its proprietary suite of intellectual property and related tools, Pure MHC Solutions works with partners seeking to elucidate how drugs and immune therapies alter, block, or enhance HLA antigen presentation to T-cells. This information can be used to determine a drug's potential efficacy, its mechanism of action, or to assist in defining the potency and tuning strategies for novel therapeutics.

Additional services and tools offered by Pure MHC Solutions also include its Peptide HLA Immunotherapy Data Resource ("PHIDR"), which is a proprietary healthy tissue database and repository used to guide TCR-based immune therapies to disease-specific targets by eliminating HLA/peptide complexes found on healthy tissues.

Pure MHC Solutions' project with argenx will support a more robust understanding of how antigen presentation changes in the presence of specific therapeutic agents, enabling more dynamic decision-making for its therapeutic programs.

"We are excited to offer our unique set of tools and services to collaborators such as argenx to assist with their autoimmune therapy programs," said Pure MHC President Kris Looney, "Pure MHC Solutions is uniquely positioned to provide access to these tools and has the deep HLA expertise that we believe will help drive better outcomes not only for our partners, but ultimately, for their patients."

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious and autoimmune diseases and allergy. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Sciences Center. Visit: www.puremhc.com

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: www.etibio.com

Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.

Related link: https://puremhc.com/

C Diff Foundation Releases ‘C diff and You’ App for Patients, Families, and Caregivers

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

The free app, "C diff and You," is available on the Apple Store and Google Play, and was designed by the C Diff Foundation as an interactive educational tool allowing users to access easy-to-understand information about C. diff. infection prevention, treatments, clinical trials, support, nutrition, diagnostics, and environmental safety.

Clostridioides difficile infection, also called C. diff., CDI, C. difficile, or CDAD, is a life-threatening infection.

"I am really pleased to see this further addition to the C Diff Foundation's catalogue of achievements. This is an ideal way to communicate information far and wide," stated Professor Mark Wilcox, MD, FRCPath.

"There are patients, families, and caregivers isolated, and experiencing social-economic changes resulting from the COVID-19 pandemic. In the Global efforts to slow the spread of the COVID-19 virus the ramifications being witnessed range from loss of wages to difficulties meeting housing, utilities, nutrition, and healthcare expenses down to basic cable and internet connections. The one common denominator remaining accessible is the Mobile (also called Cell) phone. Developing the mobile application, 'C diff and You,' places the C. diff. community in the palm of their hands continuing to support the patients, families, and caregivers who desperately need to know that they are not alone no matter where they are," says Nancy C. Caralla, Founding President, and Executive Director of the C Diff Foundation.

Through the deployment of this app, the C Diff Foundation continues with its commitment to evolve resources to unite patients, families, and healthcare providers in the fight against C. diff. infections. The app focuses on quality resources directly relevant to patients and their care providers, aiming to lower the anxiety and fear associated with a CDI and provide easy access to reliable information to all users. "C diff and You" will also provide users with direct access to patient-centered care information, educational episodes of the "C. diff. Spores and More" archived radio episodes, and the C. diff. Global Tele-Support Network with a one tap key to "Sign Up Today" for Caregiver, Nutrition, and Physician support sessions. The telephone access key connects the app user directly to the C Diff Foundation office and the Foundation's Triage Nurses.

"Patients with a C. difficile infection are in desperate need for education on the risk factors for the infection, how to stop infection spread, the chances of recurrence, and treatment options for recurrent C. difficile. The 'C diff and You' app is an outstanding and user-friendly platform for patients to get accurate information on C. difficile infection and has resources that patients can use," says Sahil Khanna, M.B.B.S., M.S.

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation
#cdiffpatientfamilycaregiver #cdiff2021 #cdiffwalks2021

C Diff Foundation™ is a trademark of The C Diff Foundation, established 2012 in the U.S.

C Diff Foundation, the leading Global Patient and Healthcare Organization Educating and Advocating for C. difficile (Clostridioides difficile, C. diff., CDAD, CDI) today announced that the organization has developed a free mobile application designed specifically for patients and families who have been impacted by a Clostridioides difficile infection.

Related link: https://cdifffoundation.org/

Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London, a leading university providing world-class teaching and cutting-edge research, to support the Phase IIa GAMECHANgER-1 clinical trial.

The trial aims to determine whether adoptive transfer of regulatory T cells (Tregs) into HLA sensitised patients can suppress memory T and B cell responses against specific HLA antigens in order to extend the longevity of donor organs.

The collaborative research is being led by Dr. Anthony Dorling, Professor of Transplant Inflammation and Repair, and Honorary Consultant Nephrologist at the Centre for Nephrology, Urology, and Transplantation, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration intends to investigate whether in vitro anti-HLA T & B cell responses in sensitized patients can be inhibited by an adoptive transfer of T regulatory cells. Under the Agreement, PTS will provide its proprietary soluble HLA (sHLA) molecules which will be used to trigger functional responses of patient cells in Fluorospot assays.

Furthermore, PTS will provide biotinylated sHLA for memory b-cell detection and characterization. Researchers hope that the results of the study will lead to a better understanding of immune tolerance, extend the duration of suppression of HLA-specific responses by Tregs and ultimately produce state-of-the-art immune therapeutics to control rejection.

"We feel that PTS has the fundamental ingredients needed to provide new sets of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins can solve a number of important challenges in DSA and B cell monitoring. With this collaboration, we are able to go beyond monitoring and help pave the way in generating immune therapeutics of the future."

"The group of highly sensitized dialysis patients that we'll be recruiting to GAMECHANgER-1 have difficulties getting a suitable kidney transplant and once transplanted suffer higher rates of rejection and complications associated with our current treatments for rejection," said Dr. Dorling. "This trial will determine whether patients' own regulatory T cells can be used to suppress immune memory responses against specific human leukocyte antigens (HLA), and if successful will pave the way for larger scale trials to determine if these regulatory cells can be used as therapy to prevent or minimise these problems in future. The HLA proteins provided by Pure Transplant Solutions are an essential tool used to tailor our immunemonitoring for individual patients, so I'm delighted to be partnering with the company to ensure a stable, long-term supply of these reagents. This trial offers a glimpse of how personalised medicine might help transform outcomes for this disadvantaged group of patients."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About King's College London

King's College London (King's) is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff. King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*).

Since its foundation, King's students and staff have dedicated themselves in the service of society. King's will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King's strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.

World-changing ideas. Life-changing impact: https://www.kcl.ac.uk/news/spotlight

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London.

Related link: https://www.puretransplant.com/

Flightpath Biosciences Launches via Illumina Accelerator to Conduct Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif. /ScoopCloud/ -- Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

* Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic

* Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes

* Company seeks to expand team to support operational acceleration and development efforts

"Today, more than ever, we understand that pathogen-driven epidemics like Lyme disease need to be more easily and accurately diagnosed and more specifically treated with narrow-spectrum, targeted therapies to avoid the microbiome damage that occurs with broad-spectrum antibiotics," said Matt Tindall, Flightpath Co-founder and CEO.

Of the 476K patients diagnosed with acute Lyme disease each year in the U.S., most are treated with broad-spectrum antibiotics, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as Persistent Lyme disease (PLD). The etiology of PLD is not understood, and objective diagnostic tools are lacking.

Interestingly, PLD symptoms overlap several diseases in which patients exhibit alterations in their microbiome. In a recent study, published in mBio (September 2020), Lewis et al determined that microbiome sequencing data alone were indicative of late-stage Lyme disease, which presents a potential, novel diagnostic tool for PLD.

The authors found that patients with post-treatment Lyme disease syndrome, a subset of PLD, had a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. Importantly, this signature supports the validity of PLD and is the first potential biological diagnostic tool for the disease.

"Our ability to analyze the microbiome, transcriptome and metabolome and identify disease signatures will give us new tools to unlock the potential of microbiome-based medicines in rare infectious diseases and potentially pathogen-driven cancers," said Mark de Souza, Flightpath Co-founder and Executive Chairman. "We're excited to get to work with the Illumina team and our world-class lab and academic partners to tackle this disease area with fresh perspectives, novel approaches and new data."

About Flightpath Biosciences

Flightpath Biosciences is developing microbiome-targeted therapeutics and advanced biomarker-based diagnostics for the treatment of infectious diseases. Flightpath's mission is to transform patient's lives with medicines developed using a multidisciplinary approach to human and pathogen biology.

Please visit us at https://flightpath.bio/ and on Twitter at https://twitter.com/FlightpathB for more information.

Media Contact:
Michael Bellas
‪(510) 859-8668‬
https://flightpath.bio/contact-us/

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0209s2p-flightpath-300dpi.jpg

Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator's second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).

Related link: https://flightpath.bio/

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas /ScoopCloud/ -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).

"The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau, CEO and Chief Scientist of Kalyagen™. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the fall of 2021, aims to evaluate the effect of ESCM in cases of heart failure. Forty-five patients who suffered from acute myocardial infarction will be randomly distributed into three groups: i) STEMREGEN® alone, ii) injection of stem cells (SVF), and iii) combined consumption of STEMREGEN® and stem cell injection. The dietary supplement will be provided at a dose of 2 capsules three times a day for 3 to 6 months. Study participants will be evaluated after 1, 3, 6 and 12 months, at which times their NYHA functional classification and echocardiographic parameters will be assessed. The first phase will begin with 15 patients.

"We have had a great deal of success treating patients suffering from advanced heart failure with stem cells," said Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy. "Unfortunately, traditional stem cell therapy utilizing Stroma Vascular Fraction is not widely available. We are hopeful that treating patients with STEMREGEN, a much more cost-effective widely-available therapy, can show similar beneficial health outcomes, and that it can further improve patient outcomes when combined with SVF therapy."

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double-blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our Website: https://www.kalyagen.com/

About Miguel Garber

Miguel Garber has over 32 years of experience in internal medicine and cardiology, with expertise in regenerative medicine, training and education, and research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Espanola de Medicina Regenerativa y Terapia Celular.

Media Contact:
Biomics, LLC (dba Kalyagen™)
Herbert Dogan
Chief Marketing Officer
(310-433-8072)
hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

###
Disclaimer: None of the statements contained in this press release have been evaluated by the Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

Related link: https://www.kalyagen.com/

Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services

AUSTIN, Texas /ScoopCloud/ -- Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

In his new role, Mr. Harlan will be responsible for leading Pure Protein's new product line commercialization while ensuring sustainable profitability and growth. He will also oversee the implementation and launch of Pure Transplant Solutions clinical diagnostics and transplant monitoring programs.

Going forward, Dr. Buchli will now be responsible for overseeing the products and services offered through HLAProtein.com in addition to expanding the portfolio of the companies' offerings. Furthermore, he will have the scientific oversight for the completion and launch of Pure Transplant Solutions' diagnostic products and monitoring programs.

"It's truly an exciting time for the Companies," said Mr. Harlan. "In the past twelve months we've built and launched our new website, established a robust pipeline of collaborations and developed new diagnostics for post-transplant monitoring. We've made the transformation from being a company solely developing technologies, to a company putting our products and tools in the hands of clinicians and researchers. We'll be launching a slate of new products and applications over the next several months and are all very excited for 2021."

"We wanted to build something more than just a website where you could place orders, we wanted to create a centralized resource for HLA research and education," said Dr. Buchli. "We've worked hard to incorporate the feedback from our collaborators and customers and are excited about the new products and services we'll be adding in the near future. In transplantation, we have ambitious goals and are optimistic about delivering solutions that improve patient outcomes."

Dr. Buchli earned his Ph.D. in Biochemistry from the University of Basel in 1996. He served as Postdoctoral Researcher at UC Davis under Drs. Sergei Grando and Dick Robbins and joined Pure Protein, LLC in March of 2001 as the Director of Research. Dr. Buchli has over 25 years of experience in molecular biology, biochemistry and immunology. As Director of Research, Dr. Buchli has developed multiple assay systems and has led the development of PTS's diagnostics portfolio.

Blake Harlan joined Emergent Technologies, Inc. (ETI) in January 2011, where his work and increasing responsibilities have focused on the commercialization of technologies spanning antimicrobials, plasma deposition, drug delivery, and immune oncology. He officially joined Pure Protein and PTS in 2016 and has been responsible for streamlining PTS's diagnostic development and commercialization strategies. He currently serves as Executive Vice President of Finance and Operations at ETI where he oversees the alignment and execution of all financial and operational objectives for ETI, its Funds and Portfolio Companies. Mr. Harlan holds a bachelor's degree in Economics from the University of Colorado at Boulder, and an MBA from the University of Texas at Austin.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies, products and services related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers the world's only and largest selection of soluble HLA (sHLA) proteins to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 2003 in order to leverage the HLA technology platform of its parent, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Today, PTS has developed a portfolio of diagnostic solutions to improve clinical outcomes related to antibody mediated rejection (AMR) and is working with collaborators to bring personalized transplant monitoring solutions to clinicians and their patients. Visit: http://www.puretransplant.com/

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0204s2p-harlan-and-buchli-300dpi.jpg

*Caption: Pure Protein, LLC and Pure Transplant Solutions, LLC Promote Blake Harlan to President and Dr. Rico Buchli to Vice President of Products and Services.

Pure Protein, LLC (Pure Protein) and subsidiary company Pure Transplant Solutions, LLC (PTS), announced today that Blake Harlan has been promoted to President and Rico Buchli, PhD to Vice President of Products and Services.

Related link: https://www.hlaprotein.com/

Pure Transplant Solutions, LLC and University Hospital Basel Announce Research Collaboration

AUSTIN, Texas /ScoopCloud/ -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel, to develop new diagnostics for DSA monitoring and characterization in transplant rejection.

The research is being led by Prof. Stefan Schaub, Senior Physician at the Kidney Transplant Center, Gideon Hönger, Senior Researcher within the Transplantation Immunology & Nephrology Department, and Dr. Rico Buchli, Director of Research at PTS and its parent company, Pure Protein, LLC. The research project aims to develop and validate new HLA-antibody affinity/avidity assays.

The initial goal of the collaboration is to gather data that supports the correlation of the measured DSA binding properties with clinical outcomes in renal allograft recipients. If successful, such data will potentially enable a new diagnostic tool delivering a numerical risk factor rating indicating the prospective severity of rejection by classifying individual DSA from 'very harmful' to 'likely harmless.'

"These non-modified and naturally folded HLA monomers of Pure Proteins are ideally suited as reaction partners for patient HLA antibodies and for our intended kinetic measurements," Mr. Hönger stated. "Several research colleagues reported high satisfaction regarding the overall quality and functionality of sHLA from Pure Protein," said Prof. Schaub.

"Today, the immunological risk of an individual transplant patient is mainly assessed by the detection of HLA antibodies and their specificity in serum using single antigen bead assays. We envision that in addition to these tests, we can develop methods to measure the kinetics of donor-specific HLA- antibody interactions with our HLA proteins. If successful, this will provide new insight into HLA antibody pathogenicity that could help improve individual patient care and ultimately increase the lifespan of transplants," said Dr. Buchli.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: http://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. (www.etibio.com) that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation. Visit: http://www.pureproteinllc.com/.

Through its new ecommerce website - http://www.hlaprotein.com/ - Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About University Hospital Basel

The University Hospital Basel is a tertiary hospital in northern Switzerland performing around 60-80 kidney transplantations per year. Further information can be found on the homepage of the hospital at https://www.unispital-basel.ch/en/ and on the clinic site at https://www.unispital-basel.ch/en/ueber-uns/bereiche/medizin/kliniken-institute-abteilungen/transplantation-immunology-nephrology/.

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0127s2p-pure-transplant-300dpi.jpg

Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The Transplantation Immunology & Nephrology Department of the University Hospital of Basel.

Related link: https://www.puretransplant.com/

Drink HRW Reports on Start of Large-Scale Randomized Controlled Trial and Preliminary Findings from Pilot Trial on the Reduction in Complications from COVID-19

COQUITLAM, BC, Canada /ScoopCloud/ -- Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results.

In addition to the French study, a team from the University of Novi Sad in Serbia has also reported promising preliminary findings from a small pilot trial administering Drink HRW tablets to patients hospitalized from COVID-19.

A statement released in France by the team of researchers stated:

Our hypothesis is that the ingestion, as early as possible at the onset of Covid-19, of 2 times 250 mL per day of water enriched in molecular hydrogen by tablets (Drink HRW, Canada) containing 80 mg of magnesium metal (capable of spontaneously releasing hydrogen on contact with water), would reduce complications in patients over the age of 60, who have just been diagnosed with Covid-19 and do not show any signs of seriousness, and may therefore be treated at home.

Our hypotheses lead to an estimate of the necessary number of 450 patients (225 in each arm, prospective, randomized, double-blind study on a product classified as a "new dietary ingredient" by the Food and Drug Administration). One of the originalities of the protocol will be that the inclusion visits will be done by teleconsultation.

The study is coordinated by the TIMC laboratory (Joint Research Unit of CNRS and Université Grenoble Alpes). The principal investigator, Dr. Yoann Gaboreau, general practitioner, is University Lecturer - Outpatient Practitioner at the Department of General Medicine of the Faculty of Medicine of Grenoble, active member of the research program "Covid-19 in ambulatory care and long-term COVID" with the REACTing consortium (REsearch and ACTion targeting emerging infectious diseases). About twenty general practitioners will be the investigators in charge of inclusions. The head of the methodology is Prof. Jean-Luc Bosson, the scientific manager is Prof. Philippe Cinquin, both Public Health Physicians. The promoter will be AGIRadom, a home health care provider expert in patient support, and which has the authorization to carry out clinical trials at home.

Despite the strong presumption of a possible interest in the ingestion of H2 at the early stages of Covid-19, no clinical trial aimed at evaluating the interest of the ingestion of H2 is currently listed on http://clinicaltrials.gov/. The test we are conducting will therefore be the first of its kind.

Drink HRW CEO Alex Tarnava added that the study will also follow patients for 1 year following recovery from COVID-19 in order to determine if the administration of hydrogen water ameliorates longer term effects from the disease.

Hydrogen therapy has emerged as a potential candidate for numerous models, including athletic performance and recovery, metabolic disorders, neurological outcomes, both acute and chronic, and even as a potential adjuvant therapy in cancer treatment. Although hydrogen therapy has not been approved for any health condition and more research is needed, there are roughly 100 publications exploring hydrogen therapy in humans demonstrating an effect from the use of hydrogen therapy, and a total of over 1500+ publications, mostly research experimenting on animals on the use of hydrogen therapy.

In February, the Chinese government added hydrogen inhalation to their approved protocol for the treatment of the novel coronavirus (*note 1). The first clinical trial in China, an open label study with 44 patients, reported promising results (*note 2). The trial was headed by Prof. Nan-Shon Zhong, famous for leading China through the SARS pandemic in 2003 and who has also acted as a senior advisor to the Chinese government throughout the COVID-19 pandemic. A larger multi-center clinical trial utilizing hydrogen inhalation is underway in China. Hydrogen-rich water has often shown a more prominent effect than hydrogen gas inhalation at much lower dosages, easier convenience, and lower cost.

Dr. Sergej Ostojic, M.D., Ph.D., professor in the department of Biomedical Sciences at the University of Novi Sad, Serbia, a noted hydrogen researcher and expert in bioenergetics, currently has ongoing clinical research exploring the Drink HRW tablets for potential effects in multiple phenotypic biomarkers of aging in the elderly, as well as the use of hydrogen water in hospitalized COVID-19 patients. He said:

"Hydrogen gas appears to inhibit airway inflammation in patients with asthma, an effect that might improve the condition of inflammatory cytokines storm seen in COVID-19. To test this hypothesis, we recently started a small-scale open-label study to evaluate the acute effects of hydrogen-rich water administration on oxygen saturation, patient-reported outcomes and other relevant biomarkers in COVID-19 patients. Preliminary findings suggest beneficial effects yet the study is still on-going and more research activities are ahead of my team. Like other promising (and urgently needed) therapeutics for COVID-19, hydrogen requires accelerated yet attentive research and approval pathways, with sufficient efficacy and safety guarantees."

Tarnava stated, "COVID-19 is a serious issue, and we at Drink HRW are ecstatic to assist in any way we can."

About Drink HRW

Drink HRW is on a mission to revolutionize the supplement industry with a new, science-based approach. In just 4 years of availability, various research teams have published 7 clinical trials and 2 case studies using their products, with an additional 15+ clinical trials and 4 preclinical research programs underway. Further, the Drink HRW technology is the only molecular hydrogen supplement on the market to obtain New Dietary Ingredient status after filing with the U.S. FDA.

For more information, please visit https://drinkhrw.com/.

MEDIA CONTACT:
Alex Tarnava
media@drinkhrw.com
(323) 475-6001

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0119s2p-drink-hrw-logo-300dpi.jpg

REFERENCES:
*(Note 1) http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf
*(Note 2) http://jtd.amegroups.com/article/view/40994/html

Drink HRW is excited to announce that a large, double-blind placebo-controlled trial is set to begin this week in France, initiated by the University of Grenoble-Alpes. At the request of the researchers, Drink HRW is supplying the hydrogen tablets for the study as well as a donation to improve the size and scope of the research. It has no other involvement in the research or the decision to publish results.

Related link: https://drinkhrw.com/

C Diff Foundation Hosts Live-Online Symposium for Patients, Families and Caregivers

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Presenters are among some of the top C diff. thought leaders and include healthcare professionals, practitioners, educators and patients who are transforming the patient experience, and changing the way people experience C. diff. infections, worldwide.

Unlike other presentations on this topic, patients will share their C. diff. infection journeys, providing a real-world perspective on the patient experience. Other topics addressed will include creating a culture for patient-centered care, C. diff. innovations, diagnostics, research, environmental safety, clinical trials and studies, C diff. in pediatric patients and more.

All presentations will be designed for the lay person to easily understand and attendees will be able to ask questions directly to the keynote speakers via a live chat feature after each presentation.

"The live chat feature is one we're excited about and believe the attendees will embrace to have their questions answered by the keynote speakers," Nancy Caralla, C Diff Foundation founding president and executive director, says.

To register for this global event, visit: https://cdifffoundation.org/patientfamilyevent/

About Clostridioides difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile, C. diff., is one of the most common cause and leading healthcare-associated infection in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20 percent, the C Diff Foundation believes that the annual incidence in the U.S. approaches 600,000.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission educating and advocating for C. diff. infection (CDI) prevention, treatments, clinical trials, environmental safety and support. Its mission continues to move forward and grow through research conducted by government, industry and academia strengthening the advocacy on behalf of patients, healthcare professionals and researchers, worldwide.

For more information: https://cdifffoundation.org/

About Seres Therapeutics

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

The Seres Therapeutics organization reported positive, topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI).

For more information: https://www.serestherapeutics.com/

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0113s2p-cdiff-symposium-300dpi.jpg

Caption: Register for the Patient and Family C Diff Foundation Symposium

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, Jan. 15 from 1 to 4 p.m. EST. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection in addition to those who are recovering or who have experienced recurrences. The patients, family members and caregivers will all benefit from the information and up-to-date data presented.

Related link: https://cdifffoundation.org/

The C Diff Foundation Assures Patients C. diff. Clinical Trials Continue to Move Forward Safely

TAMPA, Fla. /ScoopCloud/ -- While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Most Clinical trial sites have implemented protocols to disinfect, clean and maintain environmental safety for all visitors. Telehealth is also being utilized between healthcare professionals and patients who choose to participate in clinical trials.

C. diff. continues to be a leading cause of infectious disease deaths and in the U.S., nearly half a million Americans suffer from it, according to the CDC. It's important for patients to know that research is still happening to combat this infectious disease.

Even during these unprecedented times, clinical trials continue to press onward to resolve CDI's. The C Diff Foundation's mission in educating and advocating for Clostridioides difficile awareness, prevention, treatments, diagnostics, clinical trials, and environmental safety, forges ahead utilizing live, and pre-recorded media to reach health care professionals, patients, families, and caregivers worldwide.

For more information, call the C Diff Foundation at: 727-205-3922, or email: info@cdifffoundation.com.

C Diff Foundation: https://cdifffoundation.org/.

Clinical trial information: https://clinicaltrials.gov/ and https://cdiffclinicaltrials.com/

About ClinicalTrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C. difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

MEDIA CONTACT:
Kathy Bischoff
of C Diff Foundation
+1-727-205-3922
kathy@cdifffoundation.org

*LOGO link for media: https://www.Send2Press.com/300dpi/21-0111s2p-cdiff-clinical-300dpi.jpg

While some patients diagnosed with Clostridioides difficile (C. diff., C. difficile, CDI) believe they have run into clinical trial roadblocks, due to the recent focus on the pandemic, the C Diff Foundation wants them to know they are not out of options. Safe and active clinical trials continue.

Related link: https://cdifffoundation.org/

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Related link: https://www.zeteobiomed.com/

2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile, Gut Microbiome, Infection Prevention, and global healthcare-associated issues on November 14, 2020 with a live online program under the direction of IT professionals at WhiteHat Communications.

To learn more about this extraordinary conference, guest speakers, poster presentations, and the diverse topics being presented visit: https://cdiff2020.com/guest-speakers-1

All attendees will have the highest levels of online networking and learning opportunity at the Conference and Health EXPO and registration is complimentary this year. Save the date: November 4th and 5th, 2021 the 9th Annual conference will be hosted at the Boston Logan Hilton Hotel in Boston, Mass.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by a medical educational Grant from Pfizer and the members of the C Diff Foundation are profoundly grateful.

Attendee Paul Feuerstadt, MD, FACG, AGAF stated "The level of detail and data presented has a wonderful balance for those with an interest in the scientific research and interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

"I am excited to virtually meet and interact with everyone for the online extraordinaire C difficile foundation 2020 meeting. We will discuss all things C difficile and remember to tune in for my talk on the excitement of microbiome therapeutics for recurrent C difficile," stated Sahil Khanna, M.B.B.S., M.S.

The scientific data will be delivered through live virtual presentations and poster presentations at the 8th Annual International C. diff. Virtual Conference and Health Expo https://cdiff2020.com which coincides with the proclaimed; "November is Clostridioides difficile (C. diff., C. difficile) Awareness Month."

Scott Battles, VP of the C Diff Foundation stated, "We are profoundly grateful to the United States Governors for supporting our mission, along with our domestic and international partners."

November 18 - 24, 2020 Be Antibiotics Aware, a CDC educational effort, complements U.S. Antibiotic Awareness Week by providing partners with up-to-date information to help improve human antibiotic prescribing and use in the United States.

"None of us can do this alone, all of us can do this together."

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Download "C diff and You" app from Apple and Google Stores.

Twitter @cdiffFoundation #Cdiff2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

IMAGE LINKS FOR MEDIA:

[1] https://www.Send2Press.com/300dpi/30-1111s2p-cdiff8th-splash-300dpi.jpg

[2] https://www.Send2Press.com/300dpi/20-1111s2p-Cdiff640-920Conf-300dpi.jpg

C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Related link: https://cdifffoundation.org/